araag2/HINT huggingface dataset:
Clinical trial NCT01689142 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin glargine new formulation (hoe901), insulin glargine (hoe901)
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion criteria :

        o Patients with type 2 diabetes mellitus diagnosed for at least 1 year at the time of
        screening visit treated with basal insulin in combination with oral antihyperglycemic drugs
        (OADs) for at least 6 months before screening visit;

        Exclusion criteria:

          -  Age < 18 years at screening visit;

          -  BMI(body mass index) ≥ 35 kg/m2 at screening visit;

          -  HbA1c < 7.0% or > 10% (national glycohemoglobin standardization program [NGSP] value)
             at screening visit;

          -  Diabetes other than type 2 diabetes mellitus;

          -  Patients on self-monitoring of blood glucose less than 6 months before screening
             visit;

          -  Patients using pre-mix insulins, insulin detemir at 2 times or more a day, or GLP 1
             receptor agonists in the last 3 months before screening visit;

          -  Patients using mealtime insulin (rapid-acting insulin analogue and short-acting
             insulin) for more than 10 days in the last 3 months before screening visit;

          -  Use of insulin pump in the last 6 months before screening visit;

          -  Initiation of new glucose-lowering medications and/or weight loss drugs in the last 3
             months before screening visit;

          -  Severe hypoglycemia resulting in coma/seizures, and/or hospitalization for diabetic
             ketoacidosis in the last 6 months before screening visit;

          -  Unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic
             retinopathy or macular edema likely to require treatment (eg, laser, surgical
             treatment or injectable drugs) during the study period.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT00564421 (phase 3, status: completed)
Conditions: seasonal allergic rhinitis
ICD codes: J30.2
Drugs: epinastine nasal spray, low concentration, low dose volume, epinastine nasal spray, low concentration, high dose volume, epinastine nasal spray, high concentration, low dose volume, epinastine nasal spray, high concentration, high dose volume
SMILES: NC1=NCC2N1C1=CC=CC=C1CC1=CC=CC=C21, NC1=NCC2N1C1=CC=CC=C1CC1=CC=CC=C21, NC1=NCC2N1C1=CC=CC=C1CC1=CC=CC=C21, NC1=NCC2N1C1=CC=CC=C1CC1=CC=CC=C21
Eligibility criteria:

        Inclusion Criteria:

          -  A documented history of seasonal allergic rhinitis to mountain cedar or other spring
             pollen

        Exclusion Criteria:

          -  Significant medical condition

          -  Significant nasal abnormality

          -  Significant cardiac condition

          -  Recent infection

          -  Use of other allergy medication during the study

          -  Use of asthma medication other than as-needed albuterol
Clinical trial NCT00604214 (phase 3, status: completed)
Conditions: sepsis
ICD codes: A02.1, A22.7, A26.7, A32.7, A42.7, A54.86, B37.7
Drugs: drotrecogin alfa (activated), placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Must be 18 years or older

          -  Must have evidence of infection

          -  Must have systemic inflammatory response syndrome (SIRS)

          -  Must have vasopressor-dependent septic shock

        Exclusion Criteria:

          -  Have received vasopressor therapy (at any dose) for greater than 24 hours prior to the
             start of study drug

          -  Have sepsis-induced organ dysfunction for greater than 36 hours prior to the start of
             the study drug infusion

          -  Have single organ dysfunction and recent surgery (within 30 days of study entry)

          -  Have had surgery performed within the 12-hour period immediately preceding the study
             drug infusion, or are postoperative with evidence of active bleeding, or have planned
             or anticipated surgery during the infusion period

          -  Are not expected to survive 28 days given their preexisting uncorrectable medical
             condition
Clinical trial NCT00293033 (phase 3, status: completed)
Conditions: pain, cancer
ICD codes: N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: bema™, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or non-pregnant and non-lactating female. A female of child-bearing potential is
             eligible to participate in this study if she is using an acceptable method of birth
             control.

          -  18 years or older

          -  Patient must have pain associated with cancer or cancer treatment.

          -  Patient must be on a stable current regimen of oral opioids equivalent to 60 - 1000
             mg/day of oral morphine or 50 - 300 µg/hr of transdermal fentanyl (e.g. oxycodone 30
             mg, methadone 20 mg, and hydromorphone 7.5 mg).

          -  Regularly experiences 1 - 4 breakthrough pain episodes per day that require additional
             opioids for pain control

          -  At least partial relief of breakthrough pain by use of opioid therapy

          -  Subject must be able to self-administer the study medication correctly.

          -  Subject must be willing and able to complete the electronic diary card with each pain
             episode.

          -  Signed consent must be obtained at screening prior to any procedures being performed.

        Exclusion Criteria:

          -  Psychiatric/cognitive or neurological impairment that would limit the subject's
             ability to understand or complete the diary

          -  Cardiopulmonary disease that, in the opinion of the investigator, would significantly
             increase the risk of respiratory depression

          -  Recent history or current evidence of alcohol or other drug substance (licit or
             illicit) abuse

          -  Rapidly escalating pain that the investigator believes may require an increase in the
             dosage of background pain medication during the study

          -  Moderate (Grade 3) to severe (Grade 4) mucositis (Subjects with less than moderate
             mucositis are permitted and must be instructed to not apply the BEMA disc at a site of
             inflammation.)

          -  Strontium 89 therapy within the previous 6 months

          -  Any other therapy prior to the study that the investigator considers could alter pain
             or the response to pain medication.

          -  Use of an investigational drug within 4 weeks preceding this study

          -  History of hypersensitivity or intolerance to fentanyl

          -  Regularly more than 4 episodes per day

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 4 or 5

          -  Subject is pregnant, actively trying to become pregnant, breast feeding or not using
             adequate contraceptive measures
Clinical trial NCT00252967 (phase 3, status: terminated)
Conditions: atrial fibrillation, inflammation
ICD codes: I48.0, I48.21, I48.91, I48.11, I48.19, I48.20, H01.9, H30.93, H05.00, H30.003, H30.013, H30.033, H30.103
Drugs: atorvastatin, placebo
SMILES: CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    insufficient power to show therapy difference at interim analysis.
  
Eligibility criteria:

        Inclusion Criteria:

          -  > or = 18 years of age

          -  Clinical diagnosis-abnormal heart beat known as atrial fibrillation/flutter (ECG
             documentation)

          -  Able to swallow pill form of drug

        Exclusion Criteria:

          -  < 18 years of age

          -  enrollment in another ongoing trial

          -  paroxysmal atrial fibrillation

          -  hemodynamic instability

          -  atrial fibrillation ablation within 6 months of enrollment

          -  a contraindication for anticoagulation

          -  severe valvular heart disease

          -  presence of single lead implantable cardioverter defibrillator

          -  unstable angina

          -  New York Heart Association (NYHA) Class IV heart failure

          -  hyperthyroidism

          -  uncontrolled hypertension (blood pressure > 180/100 at rest) on medications

          -  an illness that would limit life expectancy to less than 1 year

          -  use of statins within the previous 30 days

          -  significant coronary artery disease or lipid abnormalities necessitating statin
             therapy

          -  implanted devices for active management of arrhythmias by pacing or defibrillation

          -  lack of access to a telephone

          -  illicit drug use

          -  alcohol abuse

          -  hypersensitivity to atorvastatin by history

          -  pregnancy

          -  sexually active female subjects not on contraception or surgically sterilized

          -  nursing mothers

          -  chronic liver disease or abnormal liver function (elevated transaminases 1.5 times the
             upper limit of normal [ULN] of laboratory reference range)

          -  severe renal disease (creatinine > 200 mmol/L)

          -  inflammatory muscle disease or creatine kinase (CK) > 3 times ULN

          -  concurrent treatment with cyclosporine, fibrates, or high-dose niacin
Clinical trial NCT01262586 (phase 3, status: completed)
Conditions: type ii diabetes mellitus
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65
Drugs: vildagliptin, glimepiride
SMILES: CN(C)C(=N)NC(N)=N, [H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes patients on stable metformin

          -  18-70 years old

          -  Willing to perform at least 4 capillary blood glucose tests per day

        Exclusion Criteria:

          -  Type 2 diabetes patients on any other antidiabetic treatment

          -  Patients listed in other trials

          -  Patients with significant diabetic organ disease or complications.

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00620282 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: liraglutide, placebo, glimepiride
SMILES: CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes

          -  Diet and lifestyle changes or metformin monotherapy for at least three months

          -  HbA1c (glycosylated haemoglobin) 6.5-9.0% (both inclusive)

          -  Body Mass Index (BMI) less than or equal to 40 kg/m^2

        Exclusion Criteria:

          -  Previous treatment with insulin (except for short term treatment with insulin in
             connection with intercurrent illness, at the discretion of the Investigator)

          -  Previous treatment with glucagon-like peptide-1 (GLP-1) analogues/mimetics, including
             treatment in a clinical trial

          -  Treatment with any oral hypoglycaemic agents other than metformin in a period of 3
             months prior to screening

          -  Current smoker or history of smoking within 6 months prior to screening

          -  Evidence of overt cardiovascular disease (documented coronary heart disease, class
             II-IV congestive heart failure, cerebrovascular disease, or peripheral vascular
             disease)

          -  Abnormal, clinically significant exercise stress electrocardiogram (ECG) test, as
             judged by the Investigator

          -  Known retinopathy or maculopathy requiring acute treatment, as judged by the
             Investigator

          -  Known autonomic neuropathy, as judged by the Investigator

          -  Initiation or change (dose or treatment regimen) in concomitant blood
             pressure-lowering or lipid-lowering medication within 4 weeks prior to screening

          -  Systolic blood pressure more than or equal to 140 mmHg and/or diastolic blood pressure
             more than or equal to 90 mmHg
Clinical trial NCT00630812 (phase 3, status: completed)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: inhaled mannitol, placebo comparator
SMILES: OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO, [Na+].[Cl-]
Eligibility criteria:

        Inclusion Criteria:

          1. Have given written informed consent to participate in this study in accordance with
             local regulations

          2. Have a confirmed diagnosis of cystic fibrosis (positive sweat chloride value ≥ 60
             mEq/L) and/or genotype with two identifiable mutations consistent with CF, accompanied
             by one or more clinical features consistent with the CF phenotype)

          3. Be aged > 6 years old

          4. Have FEV1 >40 % and < 90% predicted

          5. Be able to perform all the techniques necessary to measure lung function

        Exclusion Criteria:

          1. Investigators, site personnel directly affiliated with this study, or their immediate
             families. Immediate family is defined as a spouse, parent, child or sibling, whether
             biologically or legally adopted.

          2. Be considered "terminally ill" or eligible for lung transplantation

          3. Have had a lung transplant

          4. Be using nebulized hypertonic saline in the 4 weeks prior to visit 1

          5. Have had a significant episode of hemoptysis (>60 mL) in the three months prior to
             enrolment

          6. Have had a myocardial infarction in the three months prior to enrolment

          7. Have had a cerebral vascular accident in the three months prior to enrolment

          8. Have had major ocular surgery in the three months prior to enrolment

          9. Have had major abdominal, chest or brain surgery in the three months prior to
             enrolment

         10. Have a known cerebral, aortic or abdominal aneurysm

         11. Be breast feeding or pregnant, or plan to become pregnant while in the study

         12. Be using an unreliable form of contraception (female subjects at risk of pregnancy
             only)

         13. Be participating in another investigative drug study, parallel to, or within 4 weeks
             of visit 0

         14. Have a known allergy to mannitol

         15. Be using beta blockers

         16. Have uncontrolled hypertension - systolic BP > 190 and / or diastolic BP > 100

         17. Have a condition or be in a situation which in the Investigator's opinion may put the
             subject at significant risk, may confound results or may interfere significantly with
             the patient's participation in the study

         18. Be 'Mannitol Tolerance Test positive'

             -
Clinical trial NCT00093262 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: clevidipine, placebo
SMILES: CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(Cl)=C1Cl)C(=O)OC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Pre-randomization Inclusion Criteria:

          -  Provide written informed consent before initiation of any study-related procedures.

          -  Be at least 18 years of age

          -  Be scheduled for cardiac surgery (including Coronary Artery Bypass Grafting [CABG],
             Off Pump Coronary Artery Bypass [OPCAB], Minimally Invasive Direct Coronary Artery
             Bypass [MIDCAB] surgery, and/or valve replacement/repair procedures)

        Pre-randomization Exclusion Criteria:

          -  Women of child-bearing potential (unless they have a negative pregnancy test)

          -  Recent cerebrovascular accident (within 3 months before randomization)

          -  Known intolerance to calcium channel blockers

          -  Allergy to soybean oil or egg lecithin (components of the lipid vehicle)

          -  Pre-existing left bundle branch block or permanent ventricular pacing

          -  Any other disease or condition, which, in the judgment of the investigator would place
             a patient at undue risk by being enrolled in the trial.

          -  Participation in another therapeutic drug or therapeutic device trial within 30 days
             of starting study

        Post-randomization Inclusion Criteria:

          -  Expected to survive beyond 24 hours post-surgical procedure

          -  No surgical complications or conditions, present or anticipated, that preclude them
             from inclusion in a double blind, placebo-controlled study

          -  Determined to be hypertensive (SBP > 140 mm Hg) within 4 hours of arrival in a
             postoperative setting

          -  It is the investigator's intent to lower the patient's SBP by a minimum of 15% from
             its baseline value
Clinical trial NCT01281189 (phase 3, status: completed)
Conditions: amyotrophic lateral sclerosis
ICD codes: G12.21
Drugs: dexpramipexole, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Aged 18 to 80 years old, inclusive, on Day 1.

          -  Diagnosis of sporadic or familial ALS.

          -  Onset of first ALS symptoms within 24 months prior to Day 1.

          -  World Federation of Neurology El Escorial criteria are met for a possible,
             laboratory-supported probable, probable, or definite ALS diagnosis.

          -  Upright slow vital capacity (SVC) of 65% or more at screening.

          -  Patients taking or not taking Riluzole are eligible for this study: if a patient has
             never taken Riluzole, he or she is eligible; if a patient is currently taking
             Riluzole, he or she must have been on a stable dose for at least 60 days; if a patient
             has discontinued Riluzole, he or she must have stopped taking it for at least 30 days.

          -  Must be able to swallow tablets at the time of study entry.

        Exclusion Criteria:

          -  Other medically significant illness.

          -  Clinically significant abnormal laboratory values.

          -  Pregnant women or women breastfeeding.

          -  Prior exposure to dexpramipexole.

          -  Currently taking pramipexole or other dopamine agonists.

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT01723904 (phase 3, status: completed)
Conditions: advanced parkinson's disease
ICD codes: G20
Drugs: rotigotine
SMILES: CCCN(CCC1=CC=CS1)[C@H]1CCC2=C(O)C=CC=C2C1
Eligibility criteria:

        Inclusion Criteria:

          -  Subject is male or female, aged ≥ 30 and < 80 years at informed consent

          -  Subject has idiopathic Parkinson's Disease, of more than 3 years duration, as defined
             by the cardinal sign, bradykinesia, and the presence of at least 1 of the following:
             resting tremor, rigidity, impairment of postural reflexes, and without any known or
             suspected cause of Parkinsonism

          -  Subject has motor fluctuations such as wearing, dyskinesia

          -  Subject has experienced nocturias for at least 3 nights within 7 days prior to
             Baseline

          -  Subject is taking levodopa (L-DOPA, immediate and/or controlled release) in
             combination with benserazide or carbidopa and has been on a stable dose of L-DOPA for
             at least 28 days prior to Baseline (Visit 2)

          -  Subject is taking a non-ergot dopamine agonist (pramipexole ≤ 1.5 mg/day or ropinirole
             ≤ 6.0 mg/day) and has been on a stable dose of non-ergot dopamine agonist for at least
             28 days prior to Baseline (Visit 2)

        Exclusion Criteria:

          -  Subject is receiving therapy with tolcapone or budipine

          -  Subject is receiving therapy with one of the following drugs either concurrently or
             within 28 days prior to Baseline (Visit 2): alpha-methyl dopa, metoclopramide,
             reserpine, neuroleptics (except specific atypical neuroleptics: olanzapine,
             ziprasidone, aripiprazole, clozapine, quetiapine), monoamine oxidase A (MAO-A)
             inhibitors, methylphenidate, or amphetamine

          -  Subject has a history of symptomatic (not asymptomatic) orthostatic hypotension within
             the 6 months prior to Baseline (Visit 2)

          -  Subject has a known hypersensitivity to any components of the study medication, such
             as a history of significant skin hypersensitivity to adhesives, known hypersensitivity
             to other transdermal medications, or has unresolved contact dermatitis

          -  Subject is pregnant or nursing, or is of child-bearing potential (ie, is (i) not
             surgically sterile, or, (ii) not using adequate birth control methods [including at
             least one barrier method] or, (iii) not sexually abstinent, or (iv) not at least 2
             years post menopausal)

          -  Subject had a previous diagnosis of narcolepsy, sleep apnea syndrome, restless legs
             syndrome, or periodic limb movement disorder
Clinical trial NCT01140906 (phase 3, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: placebo, vortioxetine (lu aa21004), duloxetine
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC1=CC=C(SC2=CC=CC=C2N2CCNCC2)C(C)=C1, CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  The patient has recurrent MDD as the primary diagnosis according to DSM-IV-TR™
             criteria (classification code 296.3x)

          -  The patient has a MADRS total score >=26

          -  The patient has a CGI-S score >=4

          -  The patient has had the current episode of MDE for >3 months

        Exclusion Criteria:

          -  Any current anxiety psychiatric disorder as defined in the DSM-IV TR

          -  Current diagnosis or history of manic or hypomanic episode, schizophrenia or any other
             psychotic disorder, including major depression with psychotic features, mental
             retardation, organic mental disorders, or mental disorders due to a general medical
             condition as defined in the DSM-IV TR

          -  Current diagnosis or history of alcohol or other substance abuse or dependence
             (excluding nicotine or caffeine) as defined in the DSM-IV TR

          -  Use of any psychoactive medication 2 weeks prior to screening and during the study

          -  The patient is at significant risk of suicide or has a score >=5 on Item 10 (suicidal
             thoughts) of the MADRS, or has attempted suicide within 6 months prior to the
             Screening Visit

        Other protocol-defined inclusion and exclusion criteria may apply.